KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Liabilities: 2009-2024

Historic Total Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $33.6 billion.

  • Teva Pharmaceutical Industries' Total Liabilities fell 7.84% to $32.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 billion, marking a year-over-year decrease of 7.84%. This contributed to the annual value of $33.6 billion for FY2024, which is 4.94% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Total Liabilities stood at $33.6 billion for FY2024, which was down 4.94% from $35.4 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' Total Liabilities' 5-year high stood at $39.6 billion during FY2020, with a 5-year trough of $33.6 billion in FY2024.
  • In the last 3 years, Teva Pharmaceutical Industries' Total Liabilities had a median value of $35.4 billion in 2023 and averaged $34.8 billion.
  • Data for Teva Pharmaceutical Industries' Total Liabilities shows a maximum YoY declined of 7.98% (in 2021) over the last 5 years.
  • Over the past 5 years, Teva Pharmaceutical Industries' Total Liabilities (Yearly) stood at $39.6 billion in 2020, then decreased by 7.98% to $36.4 billion in 2021, then declined by 2.77% to $35.4 billion in 2022, then declined by 0.17% to $35.4 billion in 2023, then dropped by 4.94% to $33.6 billion in 2024.